The ınvestigation of the effect of alpha lipoic acid on lung polyphenol oxidase activity in acitretin and methotrexate given rats

Abstract

Oxidative stress is one of the main causes of lung damage caused by methotrexate (MTX). In addition, it has been observed that it causes serious side effects on other organs. In recent years, MTX has started to be used in therapy in combination with Acitretin (ACT). Alpha lipoic acid (ALA), which has antioxidant and anti-inflammatory activities, is naturally found in human foods. In this study, it was aimed to investigate the effect of ALA on phenol oxidase activity in lung tissue in the elimination of cellular level damage by free radicals produced by ACT and MTX. In the study, 50 Wistar albino male adult rats, selected from the same generation and weighing between 200 and 250 g, were used. The rats used were fed with standard mouse food and water was given free. Study groups were formed as control group (K), ALA group, ACT + MTX group and ACT + MTX + ALA group. ACT (20mg / kg / day), MTX (20mg / kg / week), ALA (50mg / kg / day) were dissolved in 0.9% NaCl and given to rats intraperitoneally. Polyphenol oxidase (PO) activation, which catalyzes the oxidation of phenolic compounds, was determined by the Hung and Boucias (1996) method. Compared to the control group, PO activity was found to be 66% higher in the MTX + ACT group and 46% higher in the MTX + ACT + ALA group. On day 5, the PO activity of the MTX + ACT + ALA group was 55% lower than in the MTX + ACT group, and this decrease was found statistically significant (p <0.05). It is determined that this decrease has reduced to 20% on the 7th day. When the results are evaluated, it can be said that MTX + ACT causes phenolic compounds in the lung cell and ALA has a protective effect against phenolic compounds originating from MTX + ACT.

Keywords

• Alpha Lipoic Acid,Acitretin,Methotrexate,Phenol Oxidase

References

1. An J, Zha D, Wu J, Li J, Teng X, Gao X, Xia Y (2017) The acitretin and methotrexate combination therapy for Psoriasis vulgaris achieves higher effectiveness and less liver fibrosis. Pharmacological research 121:158-168
2. Arpag H, Gül M, Aydemir Y, Atilla N, Yiğitcan B, Cakir T, Polat C, Þehirli Ö, Sayan M (2018) Protective Effects of Alpha Lipoic Acid on Methotrexate-Induced Oxidative Lung Injury in Rats, Journal of Investigative Surgery 31(2): 107-113
3. Carretero G, Ribera M, Belinchón I, Carrascosa JM, Puig L, Ferrandiz C, Dehesa L, Vidal D, Peral, F, Jorquera E, González-Quesada A, Munoz C, Notario J, Vanaclocha F, Moreno JC (2013) Psoriasis Group of the AEDV, Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology, Actas Dermosifiliogr. 104 (7): 598–616
4. Derm D, Dip GUM (2010) Dr. King-man HO. Medical Bulletin, 15(5)
5. Gerards AH, de Lathouder S, De Groot ER, Dijkmans BAC, Aarden LA (2003) Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 42(10): 1189-1196
6. Karadag AS, Kanbay A, Ozlu E, Uzuncakmak TK, Gedik C, Akdeniz N (2015) Pulmonary Fibrosis Developed Secondary to Methotrexate Use in a Patient with Psoriasis Vulgaris. North Clin Istanbul 2(2): 159–161
7. Lagarce L, Zenut M, Lainé-Cessac P (2015) Pharmacologie du méthotrexate. Journal de Gynécologie Obstétrique et Biologie de La Reproduction. 44(3) 203–211
8. Li S, Tan H Y, Wang N, Cheung F, Hong M, Feng Y (2018) The potential and action mechanism of polyphenols in the treatment of liver diseases. Oxidative medicine and cellular longevity. 2018

9. Lowenthal KE, Horn PJ, Kalb RE (2008) Concurrent use of methotrexate and acitretin revisited. Journal of Dermatological Treatment 19: 22–26
10. Özdemir M, Koç E (2012) Psoriasis güncel yaklaşımlar. In: Nobel Tıp kitabevleri (ed). 9th edn. Istanbul, Turkey
11. Pearce DJ, Klinger S, Ziel KK, Murad EJ, Rowell R, Feldman SR (2006) Low-Dose Acitretin Is Associated With Fewer Adverse Events Than High-Dose Acitretin in the Treatment of Psoriasis. Arch Dermatol 142:1000-1004
12. Pilkington T, Brogden RN (1992) Acitretin. Pharmacology and Therapeutic use review. Drugs 43(4): 597–627
13. Rendon A, Schäkel K (2019) Psoriasis Pathogenesis and Treatment. International Journal of Molecular Sciences 20(6): 1475
14. Rochette L, Ghibu S, Richard C, Zeller M, Cottin Y, Vergely C (2013) Direct and indirect antioxidant properties of α-lipoic acid and therapeutic potential. Mol N utr Food Res 57(1):114–125
15. Salehi B, Berkay Yılmaz Y, Antika G, Boyunegmez Tumer T, Fawzi Mahomoodally M, Lobine D, Martins N (2019) Insights on the Use of α-Lipoic Acid for Therapeutic Purposes. Biomolecules 9(8): 356
16. Souza CFD, Suarez OMZ, Silva TFM da, Gorenstein ACLA, Quintella LP, Avelleira, JCR (2016) Ulcerations Due to Methotrexate Toxicity in a Psoriasis Patient. Anais Brasileiros De Dermatologia 91(3): 375–377
17. Suh JH, Moreau R, Heath SHD, Hagen TM (2005) Dietary supplementation with (R)-α-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Report 10(1): 52-60
18. Whitaker JR (1995) Polyphenol oxidase. In Food Enzymes. Springer, Boston, MA, pp 271-307
19. WHO (2016) Global Report on Psoriasis 1.Psoriasis- Epidemiology. 2.Psoriasis – Prevention and Control. 3.Public Health. 4.Skin Diseases. I.World Health Organization. https://apps.who.int/iris/bistream/10665/204417/1/9789241565189_eng.pdf. Accessed 20 Nov 2019
20. Wu J-J, Cheng K-W, Li ETS, Wang M, Ye W-C (2008) Antibrowning Activity of MRPs in Enzyme and Fresh-Cut Apple Slice Models. Food Chemistry 109: 379-385
21. Yamauchi Y, Okazaki H, Desaki M, et al (2004) Methotrexate induces interleukin-8 production by human bronchial and alveolar epithelial cells. Clin Sci 106:619–625.